Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Monday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of Enzo Biochem stock opened at $1.13 on Monday. Enzo Biochem has a twelve month low of $0.99 and a twelve month high of $1.50. The business has a 50-day moving average price of $1.12 and a 200-day moving average price of $1.12.

Institutional Trading of Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. Renaissance Technologies LLC grew its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,499,546 shares of the medical research company’s stock after buying an additional 64,417 shares during the quarter. Renaissance Technologies LLC owned 4.86% of Enzo Biochem worth $2,725,000 at the end of the most recent reporting period. 36.90% of the stock is owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.